Quality Systems – Page 47

Stability failure misinterpreted during post-approval commitment – inspection-ready stability narrative

Assessing Stability Failure Misinterpretations During Post-Approval Commitments The complexities involved in stability studies can sometimes lead to misinterpretations of results, especially during the post-approval phase. This can create significant risks…

Process knowledge not captured during transfer to manufacturing – regulatory scrutiny implications

Understanding the Implications of Uncaptured Process Knowledge During Manufacturing Transfer The successful transfer of process knowledge from R&D to manufacturing is critical to maintain product quality and compliance. However, lapses…

Design space poorly justified during comparability assessment – how to ensure smooth tech transfer

Managing Poorly Justified Design Space in Comparability Assessments for Effective Tech Transfer In the world of pharmaceutical manufacturing and quality assurance, the process of comparability assessments is crucial during tech…

Process knowledge not captured during scale-up – CAPA during development lifecycle

Understanding the Impact of Missing Process Knowledge During Scale-Up in Pharma Development In the pharmaceutical landscape, scale-up processes are critical for transitioning from laboratory to commercial production. However, the failure…

Scale-up risk not identified during scale-up – regulatory scrutiny implications

Identifying and Addressing Scale-Up Risks During Pharmaceutical Development In the pharmaceutical industry, the transition from laboratory-scale to commercial-scale manufacturing can convey various risks that, if unaddressed, may lead to regulatory…

Scale-up risk not identified during comparability assessment – regulatory scrutiny implications

Identifying Scale-Up Risks During Comparability Assessments to Avoid Regulatory Scrutiny In pharmaceutical manufacturing, the complexity of transitioning from lab-scale to commercial-scale production can introduce significant risks, particularly if not identified…

Process knowledge not captured during pilot scale – regulatory scrutiny implications

Implications of Uncaptured Process Knowledge During Pilot Scale for Regulatory Compliance In the competitive pharmaceutical landscape, maintaining stringent adherence to regulatory standards is paramount. A common pitfall occurs when critical…

Method development instability during scale-up – data package improvements for filing

“`html Addressing Method Development Challenges During Scale-Up: An Investigative Approach to Data Package Improvements Method development instability during scale-up can lead to significant challenges in pharmaceutical manufacturing, impacting product quality,…

Tag: Quality Systems

Stability failure misinterpreted during post-approval commitment – inspection-ready stability narrative

Process knowledge not captured during transfer to manufacturing – regulatory scrutiny implications

Design space poorly justified during comparability assessment – how to ensure smooth tech transfer

Process knowledge not captured during scale-up – CAPA during development lifecycle

Scale-up risk not identified during scale-up – regulatory scrutiny implications

Scale-up risk not identified during comparability assessment – regulatory scrutiny implications

Process knowledge not captured during pilot scale – regulatory scrutiny implications

Method development instability during scale-up – data package improvements for filing

Tech transfer readiness gaps during pilot scale – CAPA during development lifecycle

Design space poorly justified during pilot scale – CAPA during development lifecycle

Design space poorly justified during scale-up – data package improvements for filing

Process knowledge not captured during transfer to manufacturing – downstream GMP risk and prevention